Differences

This shows you the differences between two versions of the page.

--- home:diseases:celiac [02.19.2019] – [recent research] sallieq
+++ home:diseases:celiac [07.20.2019] – [recent research] sallieq
@@ Line 5: / Line 5: @@
 ====== Celiac disease ======
-<relatedarticles> [[home:diseases:ibs|Irritable bowel syndrome]], [[home:diseases:ibd|Crohn's disease and ulcerative colitis]] </article>
+<relatedarticles> [[home:diseases:ibs|Irritable bowel syndrome]], [[home:diseases:ibd|Crohn's disease and ulcerative colitis]], [[home:protocol:olmesartan:safety#recent_research|Recent research into Safety of Olmesartan]] </article>
@@ Line 31: / Line 31: @@
 CONCLUSIONS: The mode of delivery and associated alterations in the development of the enteric homeostasis during the neonatal period might influence the incidence of celiac disease.  (({{pubmed>long:20478942}}))
 </blockquote>
+The emerging data on viral and bacterial microbe-host interactions and their alterations in celiac disease provides a plausible mechanism linking environmental risk and disease development. (({{pubmed>long:30519552}}))
@@ Line 63: / Line 65: @@
 [[http://science.sciencemag.org/content/356/6333/44| study in humans supports a role for infection with reovirus, a seemingly innocuous virus, in triggering the development of CeD]]
 (({{pubmed>long:28386004}})) (({{pubmed>long:26060107}}))
+Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely.  (({{pubmed>long:25023670}}))
+In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. (//presumably for bowel immunopathology caused by cytokines//). //Somewhere else I found that 1.9 million individuals are currently taking Olmesartan Medoxomil.//  //6 in 1.9 million ? Seems pretty rare to me.// (//Editor//)
+Gluten in "gluten-free" manufactured foods in Australia: a cross-sectional study.  (({{pubmed>long:30404591}})) PMID 30404591
+data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases.
+(({{pubmed>long:30594690}}))
 {{tag>diseases }}

home/diseases/celiac.txt · Last modified: 09.14.2022 by 127.0.0.1